PureTech Health plc (LON:PRTC)
London · Delayed Price · Currency is GBP · Price in GBX 121.60
-4.40 (-3.49%)
Sep 4, 2026, 4:35 PM GMT
PureTech Health Revenue
In the year 2025, PureTech Health had annual revenue of $4.66M USD, down -3.50%. PureTech Health had revenue of $2.81M in the half year ending December 31, 2025, with 1,460.00% growth.
Revenue
$4.66M
Revenue Growth
-3.50%
P/S Ratio
85.51
Revenue / Employee
$51.77K
Employees
90
Market Cap
296.00M GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.66M | -169.00K | -3.50% |
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | 20.75M | 18.21M | 718.46% |
| Dec 31, 2017 | 2.54M | -1.90M | -42.79% |
| Dec 31, 2016 | 4.43M | -7.40M | -62.54% |
| Dec 31, 2015 | 11.83M | 9.61M | 432.31% |
| Dec 31, 2014 | 2.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Nanopore Technologies | 235.00M |
| Oxford Biomedica | 168.74M |
| Bioventix | 12.54M |
| Scancell Holdings | 4.71M |
| 4basebio | 1.69M |
| Ondine Biomedical | 1.43M |
| Faron Pharmaceuticals Oy | 1.14M |
PureTech Health News
- 10 days ago - PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress - Business Wire
- 7 weeks ago - PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Business Wire
- 2 months ago - PureTech entity Celea raises $180 million to move lung disease drug into late stage trial - Reuters
- 2 months ago - PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) - Business Wire
- 2 months ago - PureTech Health: Results of Annual General Meeting - Business Wire
- 4 months ago - PureTech Health Earnings Call Transcript: H2 2025 - Transcripts
- 4 months ago - PureTech Health Annual report: H2 2025 - Filings
- 4 months ago - PureTech Health Annual report: H2 2025 - Filings